Trofosfamide
Appearance
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Ixoten |
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth (film-coated tablets) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.040.686 |
Chemical and physical data | |
Formula | C9H18Cl3N2O2P |
Molar mass | 323.58 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Trofosfamide (INN) is a nitrogen mustard alkylating agent. It is sometimes abbreviated "TRO".[1] It has been used in trials to study its effects on ependymoma, medulloblastoma, sarcoma, soft tissue,[clarification needed] supratentorial PNET, and recurrent brain tumors.[2]
References
- ^ Jahnke K, Thiel E, Bechrakis NE, et al. (December 2008). "Ifosfamide or trofosfamide in patients with intraocular lymphoma". J. Neurooncol. 93 (2): 213–7. doi:10.1007/s11060-008-9761-8. PMID 19099202. S2CID 33892177.
- ^ "Trofosfamide". www.drugbank.ca. Retrieved 2019-12-19.